AbbVie Endocrine Inc. v. Takeda Pharm. Co.

Full title: AbbVie Endocrine Inc. v. Takeda Pharmaceutical Company Limited,

Court: Court of Chancery of Delaware

Date published: Sep 17, 2021

C. A. 2020-0953-SG (Del. Ch. Sep. 17, 2021)

Opinion

C. A. 2020-0953-SG

09-17-2021

AbbVie Endocrine Inc. v. Takeda Pharmaceutical Company Limited,

A. Thompson Bayliss, Esquire Joseph A. Sparco, Esquire ABRAMS & BAYLISS LLP Kevin R. Shannon, Esquire Christopher N. Kelly, Esquire Daniel M. Rusk, IV, Esquire POTTER ANDERSON & CORROON LLP

Sam Glasscock, III Vice Chancellor

A. Thompson Bayliss, Esquire Joseph A. Sparco, Esquire ABRAMS & BAYLISS LLP

Kevin R. Shannon, Esquire Christopher N. Kelly, Esquire Daniel M. Rusk, IV, Esquire POTTER ANDERSON & CORROON LLP

Dear Counsel:

I have considered the Defendant's Motion to Supplement the Trial Record, the Plaintiff's Motion to Supplement the Trial Record (together, the "Cross-Motions") and the Plaintiff's Limited Opposition to Defendant's Motion to Supplement the Trial Record.

The Cross-Motions are hereby granted, with the exception of Exhibit 1 to the Defendant's Motion ("Exhibit 1"), which is a gloss on disputed facts that would require supplemental discovery in order for the Plaintiff to address. In any event, Exhibit 1 is not dispositive of my decision.

To the extent the foregoing requires an order to take effect, it is SO ORDERED.

Sincerely,

Sam Glasscock, III Vice Chancellor